# Robust Computational Extraction of Non-Enhancing Hypercellular Tumor Regions from Clinical Imaging Data

arXiv: https://arxiv.org/abs/2601.17802 · HTML: https://mlsanity.com/paper/2601.17802/

## Key facts

- No citing papers in the map yet (data through 14 Oct 2026).
- Builds on 7 of its 42 references that are in the map.
- First posted on arXiv 25 Jan 2026.

## Builds on (most cited first, 7 of 7)

- [UNETR: Transformers for 3D Medical Image Segmentation](https://mlsanity.com/paper/2103.10504/) (2021)
- [The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification](https://mlsanity.com/paper/2107.02314/) (2021)
- [Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge](https://mlsanity.com/paper/1811.02629/) (2018)
- [Efficient Multi-Scale 3D CNN with Fully Connected CRF for Accurate Brain Lesion Segmentation](https://mlsanity.com/paper/1603.05959/) (2016)
- [UNETR++: Delving into Efficient and Accurate 3D Medical Image Segmentation](https://mlsanity.com/paper/2212.04497/) (2022)
- [The Rio Hortega University Hospital Glioblastoma dataset: a comprehensive collection of preoperative, early postoperative and recurrence MRI scans (RHUH-GBM)](https://mlsanity.com/paper/2305.00005/) (2023)
- [A Bayesian approach to tissue-fraction estimation for oncological PET segmentation](https://mlsanity.com/paper/2003.00317/) (2020)

## Abstract (arXiv)

Accurate identification of non-enhancing hypercellular (NEH) tumor regions is an unmet need in neuro-oncological imaging, with significant implications for patient management and treatment planning. We present a robust computational framework that generates probability maps of NEH regions from routine MRI data, leveraging multiple network architectures to address the inherent variability and lack of clear imaging boundaries. Our approach was validated against independent clinical markers -- relative cerebral blood volume (rCBV) and enhancing tumor recurrence location (ETRL) -- demonstrating both methodological robustness and biological relevance. This framework enables reliable, non-invasive mapping of NEH tumor compartments, supporting their integration as imaging biomarkers in clinical workflows and advancing precision oncology for brain tumor patients.